The research of association between HBV prevalence and socioeconomical status after universal vaccination in children, in Manisa;Manisa i̇lindeki çocuklarda kitlesel hepatit b aşilamasi sonrasi HBV Prevalansinin Sosyoekonomik Durumla İlişkisinin Araştirilmas?

Turkiye Klinikleri Pediatri

Volumn 19, Issue 2, 2010, Pages 118-126

  Tosun, Selma ^a   Deveci, Serol ^b   Kaplan, Yunus ^b   Kasirga, Erhun ^c  

^a Enfeksiyon Hastaliklari ve   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

^c CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Child; Hepatitis B antibodies; Socioeconomic factors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CARRIER; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; PRIMARY SCHOOL; SCHOOL CHILD; SEROPREVALENCE; SOCIOECONOMICS; VACCINATION;

EID: 77953801312     PISSN: 13000381     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008;13(21). pii: 18880.
2. Mistik R. [Epidemiology of viral hepatitis in Turkey-To discussion of publications]. Tabak F, Balik İ, Tekeli E, editörler. Viral Hepatit 2007. Birinci Baski. İstanbul: Viral Hepatitle Savaşim Derneǧi Yayini. Oban Matbaasi; 2007. p.9-50.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;(34 Suppl 1):S1-3.
4. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990;8 (Suppl):S129-33.
5. Centers for Disease Control (CDC). Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep 1984;33(21): 285-90.
6. Reesink HW, Reerink-Brongers EE, Lafeber-Schut BJ, Kalshoven-Benschop J, Brummelhuis HG. Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin. Lancet 1979;2(8140):436-8.
7. Centers for Disease Control (CDC). Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 1988;37(22):341-6, 351.
8. Zamir C, Dagan R, Zamir D, Rishpon S, Fraser D, Rimon N, et al. Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen-positive/ hepatitis B e antigen-negative carriers. Pediatr Infect Dis J 1999;18(3):262-6.
9. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(RR-13):1-25.
10. World Health Organization. Hepatitis B vaccines WHO position paper. Weekly Epidemiological Record. No.40, Vol.84. Geneva: World Health Organization; 2009. p.405-20.
11. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995;274(15):1201-8.
12. Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64(11):2377-80.
13. Chen CC, Yen CH, Wu WY, Hu SW, Chen SC, Bell WR, Lee MC. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. Chin Med J (Engl) 2007;120(13):1155-8.
14. Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program. J Med Virol 2007;79(2):138-43.
15. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J 2005;11(1-2):62-7.
16. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007; 16(4):403-6.
17. Kojouharova M, Teoharov P, Bahtchevanova T, Maeva I, Eginlian A, Deneva M. Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian new-borns. Infection 2001;29(6):342-4.
18. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999;17(23-24):2946-50.
19. Centers for Disease Control (CDC). Global Progress Toward Universal Childhood Hepatitis B Vaccination. MMWR 2003;52(36):868-70.
20. Kalkan A, Bulut V. [Hepatitis B vaccine]. Turkiye Klinikleri J Inf Dis-Special Topics 2008;1(1):5-11.
21. Tosun S. [An evaluation of universal hepatitis B vaccination in Turkey]. VII. Ulusal Viral Hepatit Kongre Kitabi. Birinci Baski. Ankara: Viral Hepatitle Savaşim Derneǧi Yayini; 2004. p.11-6.
22. Tosun SY, Karaca M, Ertilav M, Akkum K. [The evaluation of hepatitis B vaccine efficacy used in health care centers]. Turkiye Klinikleri J Pediatr 2003;12(2):77-80.
23. Tosun SY, Eser E, Sir E, Bayindirli D, İrençin D, Obali Ç. [Investigation of the vaccine level of protection four years later in children who were included in hepatitis B vaccination programme in 1998 in manisa]. MN Klinik Bilimler& Doktor 2003;9(4):459-66.
24. Mistik R, Balik İ. [The viral hepatitis epidemiology in Turkey]. Kiliçturgay K, editör. Viral Hepatit 1998. Birinci Baski. Bursa: Viral Hepatitle Savaşim Derneǧi Yayini, Deniz Ofset; 1998. p.9-40.
25. Lin DB, Wang HM, Lee YL, Ling UP, Changlai SP, Chen CJ. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 1998;16(17): 1683-7.
26. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007;132(4):1287-93.